Multiple sclerosis (MS) is an autoimmune disorder of the CNS characterized by inflammation, demyelination and axonal loss. Classical evidence in experimental allergic encephalomyelitis, the animal model of MS, support the relevance of sympatoadrenergic as well as of dopaminergic mechanisms. In MS patients, dysregulation of adrenergic and dopaminergic pathways contribute to the disease in immune system cells as well as in glial cells. Available evidence is summarized and discussed also in the light of the novel role of dopamine, noradrenaline and adrenaline as transmitters in immune cells, providing a conceptual frame to exploit the potential of several dopaminergic and adrenergic agents, already in clinical use for non-immune indications and with a usually favourable risk-benefit profile, as add-on drugs to conventional immunomodulating therapies in MS.

Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

COSENTINO, MARCO
;
MARINO, FRANCA
2013-01-01

Abstract

Multiple sclerosis (MS) is an autoimmune disorder of the CNS characterized by inflammation, demyelination and axonal loss. Classical evidence in experimental allergic encephalomyelitis, the animal model of MS, support the relevance of sympatoadrenergic as well as of dopaminergic mechanisms. In MS patients, dysregulation of adrenergic and dopaminergic pathways contribute to the disease in immune system cells as well as in glial cells. Available evidence is summarized and discussed also in the light of the novel role of dopamine, noradrenaline and adrenaline as transmitters in immune cells, providing a conceptual frame to exploit the potential of several dopaminergic and adrenergic agents, already in clinical use for non-immune indications and with a usually favourable risk-benefit profile, as add-on drugs to conventional immunomodulating therapies in MS.
2013
Adrenaline; Adrenoceptors; Dopamine; Dopaminergic receptors; Lymphocytes; Multiple sclerosis; Neuroimmunology; Noradrenaline
Cosentino, Marco; Marino, Franca
File in questo prodotto:
File Dimensione Formato  
J_Neuroimmune_Pharmacol_2013_8_163_179.pdf

non disponibili

Descrizione: PDF EDITORIALE
Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 669.85 kB
Formato Adobe PDF
669.85 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/1789719
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 74
  • ???jsp.display-item.citation.isi??? 70
social impact